Alivus Life Sciences Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹1,436.90
-13.00-0.90% (1D)
As on 20 Nov 2026 at 15:54
As of 20 Nov 2026 at 15:54, Alivus Life Sciences Ltd is trading at ₹1,436.90. The 52-week range stands at ₹819.00–₹1,574.00, with a market cap of ₹17.64 thousand crore. At a P/E of 25.62 and a dividend yield of 0.35%, it is a mid-cap stock in the Pharmaceuticals sector.

ALIVUS Price Chart

Market Cap
₹17.64K Cr
PE Ratio
25.62
ROCE
24.26%

Alivus Life Sciences Ltd Performance

Alivus Life Sciences Ltd Fundamentals

Know More
Market Cap₹17.64K Cr
ROE18.44%
P/E Ratio (TTM)25.62
EPS (TTM)₹55.98
P/B Ratio4.86
Dividend Yield0.35%
Industry P/E91.72
Book Value₹295.31
Debt to Equity0.01
Face Value₹2

Alivus Life Sciences Ltd Shareholding Pattern

Know More
Promoter74.8%
Foreign Institutions5.9%
Mutual Funds5.3%
Domestic Institutions1.7%
Public12.2%

Alivus Life Sciences Ltd Financial Statements

Know More
No data for this view.

Alivus Life Sciences Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Alivus Life Sciences

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company. The Company is a leading, independently managed developer and manufacturer of select, high-value, non-commoditised Active Pharmaceutical Ingredients (APIs), with a strong presence across chronic therapeutic segments. In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL. The Company expanded projects with additional 240 KL at Dahej in 2023. The brownfield expansion at Dahej for Oncology Plant was completed. Out of the 2 independent modules, one module commissioned 100%. 192 KL out of the 400 KL intermediate manufacturing block at Ankleshwar commissioned in 2023. The Company came up with an IPO of 21,022,222 Equity Shares comprising a Fresh Issue of 14,722,222 Equity Shares and Offer for Sale of 6,300,000 Equity Shares aggregating to Rs 1513.6 Crores in August, 2021. FY24 ushered in a new chapter with Nirma Limited, a diversified conglomerate with interests in consumer products, cement, chemicals, and pharmaceuticals, acquiring a majority stake in GLS. In FY 2023-24, 75% of the equity stake of the Company was transferred by the promoter, Glenmark Pharmaceuticals Limited (GPL) to Nirma Limited on March 6, 2024. Resulting this, there was a change in ownership status via share purchase agreement, and Nirma became the new promoter of the Company. In 2026, the Company commissioned its first continuous manufacturing block at Ankleshwar. Two independent modules were commissioned in FY 2025 and made operational at Dahej. The installed reactor capacity stood at 1,424 KL in FY26, while annual API production volumes increased to 888 MT, across the multi-purpose facilities.

Parent Organisation—
Founded2011
Managing DirectorYasir Yusufali Rawjee
NSE SymbolALIVUS

Alivus Life Sciences Ltd Resistance and Support levels

R31,479.23R21,469.22R11,463.04S11,443.02S21,436.84S31,426.831,436.90

Alivus Life Sciences Ltd Technicals

Current Price
₹1,436.90 ₹13.00 (-0.90%)
Bearish
4
Bullish
8
  • 20 Day0.1%
  • 50 Day3.4%
  • 100 Day8.8%
  • 200 Day17.9%

Alivus Life Sciences Ltd Latest News

View More
11 NOV 2026 | Wednesday
Alivus Life Sciences acquires 65.01% stake in IQGEN-X Pharma, making it a subsidiary
29 OCT 2026 | Thursday
Alivus Life Sciences’ board approved allotment of shares to employees exercising stock options
22 OCT 2026 | Thursday
Alivus Life Sciences to review financial results at board meeting October 29, 2026
21 OCT 2026 | Wednesday
Alivus Life Sciences to review financial results at board meeting October 29, 2026
18 AUG 2026 | Tuesday
Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma for approximately Rs 9.12 crores
06 AUG 2026 | Thursday
Alivus Life Sciences recommends Rs 5.00 per share dividend at September 2026 meeting
30 JUL 2026 | Thursday
Alivus Life Sciences’ board approved allotment of shares to employees exercising stock options
30 JUL 2026 | Thursday
Alivus Life Sciences reports Rs 1,601 million net profit, revenue up 6.4% year-over-year
24 JUL 2026 | Friday
Alivus Life Sciences to table results
24 JUL 2026 | Friday
Alivus Life Sciences to discuss results

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Alivus Life Sciences Ltd is ₹1,436.90 as of 20 Nov 2026 at 15:54.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now